EP2508188
Lyfjasamsetningar sem innihalda dapaglíflosín-própýlen-glýkól-hýdrat
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
21.3.2008EP published:
10.5.2023EP application number:
12153939.9
EP translation filed:
10.7.2023Grant published:
15.8.2023EPO information:
European Patent Register
Max expiry date:
20.3.2028Expiry date:
20.3.2027Next due date:
31.3.2027
Title in English:
Pharmaceutical formulations containing dapagliflozin propylene glycol hydrateLanguage of the patent:
English
Timeline
Today
21.3.2008EP application
10.5.2023EP Publication
10.7.2023Translation submitted
15.8.2023Registration published
20.3.2027Expires
Owner
Name:
AstraZeneca ABAddress:
151 85 Södertälje, SE
Inventor
Name:
Bindra, DilbirAddress:
New Brunswick, NJ 08903, US
Name:
Dali, Mandar V.Address:
Bridgewater, New Jersey 08807, US
Name:
Parab, Prakash V.Address:
New Brunswick, NJ 08903, US
Name:
Patel, Jatin M.Address:
New Brunswick, NJ 08903, US
Name:
Tao, LiAddress:
New Brunswick, NJ 08903, US
Name:
Tejwani, Ravindra W.Address:
New Brunswick, NJ 08903, US
Name:
Vatsaraj, NipaAddress:
New Brunswick, NJ 08903, US
Name:
Wu, YongmeiAddress:
New Brunswick, NJ 08903, US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
896286 PDate:
22.3.2007Country:
US
Classification
Categories:
A61K 31/70, A61P 3/10, A61K 9/16, A61K 9/20
Annual fees
Number
Paid
Expires
Payer
Number: 17
Paid: 26.3.2024
Expires: 20.3.2025
Payer: Árnason Faktor ehf.
Number: 18
Paid: 7.3.2025
Expires: 20.3.2026
Payer: Árnason Faktor ehf.
Number: 19
Paid: 20.3.2026
Expires: 20.3.2027
Payer: Árnason Faktor ehf.